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Abstract 
N,N-Diallyltryptamine (DALT) and 5-methoxy-DALT (5-MeO-DALT) are synthetic tryptamine 
derivatives that are commonly referred to the so-called new psychoactive substances (NPS). They 
show psychoactive effects similar that may be similar to other tryptamine derivatives. The aims of the 
present work were to study the metabolic fate and detectability in urine after intake of DALT and 
5-MeO-DALT. For metabolism studies, rat urine samples obtained following high dose 
administration were prepared by precipitation and analyzed by liquid chromatography-high 
resolution-mass spectrometry (LC-HR-MS/MS). According to the identified metabolites, multiple 
aromatic and aliphatic hydroxylations, N-dealkylation, N-oxidation, and combinations thereof could 
be proposed as main metabolic pathways for both compounds. O-Demethylation was additionally 
found for 5-MeO-DALT and extensive glucuronidation or sulfation for both compounds after phase I 
transformation. The cytochrome P450 (CYP) isoenzymes predominantly involved in DALT 
metabolism were CYP2C19, CYP2D6, and CYP3A4 and those mainly involved in 5-MeO-DALT 
metabolism were CYP1A2, CYP2C19, CYP2D6, and CYP3A4, respectively. For the detectability 
studies, rat urine samples were screened by the authors’ GC-MS, LC-MSn, and LC-HR-MS/MS urine 
screening approaches following administration of low doses. The LC-MSn and LC-HR-MS/MS 
approaches were deemed suitable for monitoring consumption of both compounds. The most 
abundant targets were a ring hydroxy metabolite of DALT or the N,O-bis-dealkyl metabolite of 
5-MeO-DALT as well as their glucuronides. The GC-MS approach only allowed for the screening of 
DALT via its main metabolites. 
 
Keywords designer drugs; DALT; 5-MeO-DALT; metabolism; SUSA; LC-HR-MS/MS
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Introduction 
 
Synthetic tryptamines belong to one class of new psychoactive substances (NPS) in addition to 
synthetic cannabinoids, phenethylamines, synthetic cathinones, and others [1, 2]. They interact with 
the serotonergic system, which includes activation of the 5-HT1A and 5-HT2A receptor subtypes [3] 
and increase of serotonin release [4-8]. Active oral dosage levels of N,N-diallyltryptamine (DALT) 
and 5-methoxy-DALT (5-MeO-DALT) have been suggested to range from above 40 mg for DALT 
and 12-20 mg for 5-MeO-DALT, respectively [9-11]. Their chemical structures are depicted in Fig. 
1. The control status of both substances differs across the globe. Misuse of 5-MeO-DALT and the 
association with adverse effects has been recently reported [12, 13], which serves as a reminder that 
the ability to carry out suitable toxicological analysis is urgently needed. As far as DALT is 
concerned, no corresponding data are available. 
Analytical methods used for the characterization of N,N-dialkylated tryptamines [14] and 
naturally-occurring N,N-dimethylated tryptamines found in psychoactive beverages [15] have been 
reviewed but without reference to determination in biofluids. Information on metabolism in urine is 
important so that appropriate targets can be identified. Katagi et al. reviewed the general metabolic 
steps and toxicologic analysis of a number of selected 5-methoxy-N,N-dialkyltryptamines [16]. 
Metabolism and detectability of DALT and 5-MeO-DALT in relevant matrices have not yet been 
described. Therefore, the aim of the present work was to identify phase I and II metabolites of DALT 
and 5-MeO-DALT in rat urine as well as in pooled human liver microsomes (pHLM) by liquid 
chromatography (LC)-high resolution (HR)-MS/MS and to identify the human cytochrome-P450 
(CYP) isoenzymes involved in the main metabolic steps. Furthermore, the detectability of DALT and 
5-MeO-DALT in urine by the authors’ urine screening approaches (SUSA) using GC-MS, LC-MSn, 
or LC-HR-MS/MS was tested. 
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Experimental 
 
Chemicals and reagents 
 
DALT, DALT-d4, and 5-MeO-DALT were synthesized following established methods [17], 
isocitrate and isocitrate dehydrogenase from Sigma (Taufkirchen, Germany), NADP+ from Biomol 
(Hamburg, Germany), acetonitrile (LC-MS grade), ammonium formate (analytical grade), formic 
acid (LC-MS grade), methanol (LC-MS grade), and all other chemicals and biochemicals from VWR 
(Darmstadt, Germany). The baculovirus-infected insect cell microsomes (Supersomes) containing 1 
nmol/mL of human cDNA-expressed CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, 
CYP2D6, CYP2E1 (2 nmol/mL), CYP3A4, or CYP3A5 (2 nmol/mL), and pooled human liver 
microsomes (pHLM, 20 mg microsomal protein/mL, 400 pmol total CYP/mg protein) were obtained 
from BD Biosciences (Heidelberg, Germany). After delivery, the microsomes were thawed at 37 °C, 
divided into aliquots, snap-frozen in liquid nitrogen, and stored at -80 °C until use.  
 
Urine samples 
 
As usual, investigations were performed using rat urine samples from male Wistar rats (Charles 
River, Sulzfeld, Germany) for toxicological diagnostic reasons. The compound was administered 
once in an aqueous suspension by gastric intubation in a single 20 mg/kg body mass (BM) dose for 
the identification of the metabolites and once in a single 1 mg/kg BM dose for toxicological analysis. 
The rats were housed in metabolism cages for 24 h, having water ad libitum. Urine was 
collected separately from feces over a 24 h period. Blank urine samples were collected before drug 
administration to confirm the absence of interfering compounds. The samples were directly analyzed 
and then stored at -20 °C. 
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Sample preparation for identification of phase I and II metabolites by LC-HR-MS/MS 
 
As described previously [18], 500 µL of acetonitrile was added to 100 µL of urine. The mixture was 
shaken on a rotary shaker for 2 min. After centrifugation for 2 min at 10,000×g, 500 µL was 
transferred into a glass vial and evaporated to dryness under a gentle stream of nitrogen at 70 °C. The 
residue was dissolved in 50 µL of methanol. A 10-µL aliquot of each extract was then injected onto 
the LC-HR-MS/MS system. 
 
Microsomal incubations f r pHLM and initial CYP activity screening studies 
 
Conditions for the performance of the microsomal incubations for each isomer were published 
previously [19]. Briefly, drugs (50 µmol/L each) were incubated with the CYP isoenzymes (50 
pmol/mL, each) CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, 
CYP3A4, CYP3A5, or pHLM (1 mg protein/mL) for 30 min. Reactions were initiated by addition of 
the substrate and stopped with 50 µL of ice-cold acetonitrile containing DALT-d4 (1 mg/L) as internal 
standard. The solution was centrifuged for 2 min at 14,000×g, 50 µL of the supernatant phase were 
transferred to a glass vial and a 10-µL aliquot injected onto the LC-HR-MS/MS system. 
 
LC-HR-MS/MS apparatus for identification of phase I and II metabolites in urine and microsomal 
incubations 
 
According to published procedures [20], the extracts were analyzed using a Accela LC system 
consisting of an HTC PAL autosampler, a degasser, two 1250 quaternary pumps, an Aria Transcend 
TLX-I HTLC system, and a valve interface module with built-in switching valves, all controlled by 
the Aria software version 1.6.3, coupled to a Q-Exactive system equipped with a heated electrospray 
ionization (HESI)-II source and Xcalibur 2.2 SP1.48 software (all of ThermoFisher, Dreieich, 
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Germany). Mass calibration was done according to the manufacturer’s recommendations every 72 h 
using external mass calibration. According to Helfer et al. (submitted for publication), the LC 
conditions were as follows: a ThermoFisher Accucore PhenylHexyl column (100 mm × 2.1 mm I.D., 
2.6 µm), guarded by an UHP filter cart (0.5 µm). Chromatography was performed at 35 °C 
maintained by an analytical column heater (HotDog 5090, Prolab, Reinach, Switzerland). The mobile 
phases consisted of 2 mM aqueous ammonium formate plus 0.1% formic acid (pH 3, eluent A) and 2 
mM aqueous ammonium formate with acetonitrile:methanol (50:50, v/v; 1% water) plus 0.1% formic 
acid (eluent B). The flow rate was set to 0.5 mL/min for 10 min and 0.8 mL/min from 10-13.5 min. 
The gradient was programmed as follows: 0-1.0 min 99% A, 1-10 min to 1% A, 10-11.5 min hold 1% 
A, 11.5 - 13.5 min hold 99% A. The HESI-II source conditions were as follows: heater temperature, 
320 °C; sheath gas, 60 arbitrary units (AU); auxiliary gas, 10 AU; spray voltage, 3.00 kV; capillary 
temperature, 320 °C; and S-lens RF level, 60.0. Mass spectrometry was performed in positive 
ionization mode using full scan mode and a subsequent data-dependent acquisition (DDA) mode. The 
settings for the full scan mode were as follows: scan range, m/z 130-1000; resolution, 35,000; 
microscans, 1; automatic gain control (AGC) target, 1e6; and maximum injection time (IT), 120 ms. 
The settings for the DDA mode were as follows: resolution, 17,500; microscans, 1; AGC target, 2e5; 
maximum IT, 250 ms; loop count, 5; isolation window, m/z 1.0; high collision dissociation (HCD) 
cell stepped normalized collision energy (NCE), 17.5, 35, and 52.5%; spectrum data type, profile; 
intensity threshold, 4.0e3; dynamic exclusion, 8.0 s. 
 
GC-MS SUSA 
 
According to published procedures [21], the urine sample (5 mL) was divided into two aliquots where 
one part was submitted to acid hydrolysis followed by extraction of the combined parts with a 
dichloromethane-isopropanol-ethyl acetate mixture. After evaporation, the residue was acetylated 
with an acetic anhydride-pyridine mixture under microwave irradiation, again evaporated and 
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reconstituted in 100 µL of methanol. A 1-µL aliquot was injected onto the GC-MS system. This 
consisted of a Hewlett Packard (HP, Agilent, Waldbronn, Germany) 5890 Series II gas 
chromatograph combined with an HP 5972A MSD mass spectrometer and an HP MS ChemStation 
(DOS series) with HP G1034C software version C03.00. The GC conditions were as follows: 
splitless injection mode; column, ThermoFisher TG-1MS capillary (12 m x 0.2 mm I.D.); 
cross-linked methyl silicone, 330 nm film thickness; injection port temperature, 280 °C; carrier gas, 
helium; flow rate, 1 mL/min; column temperature, programmed from 100 to 310 °C at 30 °C/min; 
initial time, 2 min; final time, 5 min. The MS conditions were as follows: full scan mode, m/z 50-550; 
electron ionization (EI) mode, ionization energy, 70 eV; ion source temperature, 220 °C; and 
capillary direct interface, 280 °C [22]. 
The full scan data files were evaluated by the automated mass spectral deconvolution and 
identification system (AMDIS) (http://chemdata.nist.gov/mass-spc/amdis/) in simple mode. The 
target library was a modified version of the Maurer/Pfleger/Weber MPW_2015 library [23]. The 
deconvolution parameter settings were as follows [24]: width, 32; adjacent peak subtraction, 2; 
resolution, high; sensitivity, very high; shape requirements, low; minimum match factor, 50. 
 
LC-MSn SUSA 
 
The workup was identical to the procedure described above for identification of phase I and II 
metabolites. Analysis was performed using a LXQ linear ion trap MS equipped with an HESI II 
source and coupled to an Accela LC system (all from ThermoFisher). The LC and the MS settings 
were described elsewhere [18]. Briefly, DDA was conducted on precursor ions selected from MS1: 
MS1 was performed in the full scan mode (m/z 100-800) and MS2 and MS3 were performed in the 
DDA mode. ThermoFisher Xcalibur 2.2 SP1.48 software was used for data acquisition, NIST MS 
Search 2.0 (National Institute of Standards and Technology, Gaithersburg, MD, USA) for library 
generation, ThermoFisher ToxID 2.1.1 for automatic target screening in the MS2 screening mode. 
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The settings were as follows: retention time (RT) window, 20 min; RT, 0.1 min; signal threshold, 
100; search index, 600; and reverse search index, 700. ToxID was run automatically after file 
acquisition using a Xcalibur processing method starting the software tool. The target library was a 
modified version of the Maurer/Wissenbach/Weber MWW_2014 library [25].  
 
LC-HR-MS/MS SUSA 
The workup and the LC-HR-MS/MS method were the same as described above for identification of 
phase I and II metabolites. ThermoFisher TraceFinder Clinical Research 3.2 software was used for 
data evaluation as described by Helfer et al. (submitted for publication). 
 
 
Results and discussion 
 
Identification of the phase I and phase II metabolites by LC-HR-MS/MS 
 
The structures of the urinary metabolites were deduced from their MS/MS spectra in correlation to 
the spectra of the parent compounds. The fragmentation patterns were postulated based on 
established rules [26]. The LC-HR-MS/MS spectra of DALT and its phase I metabolites are given in 
Fig. S1, those of 5-MeO-DALT and its phase I metabolites in Fig. S2 supplied as electronic 
supplementary material. The LC-HR-MS/MS spectra of the phase II metabolites of DALT are given 
in Fig. S3 and those of 5-MeO-DALT in Fig. S4, respectively. In addition, the proposed chemical 
structures, accurate masses of the ions, calculated elemental formulas, and mass error values in parts 
per million (ppm) are given in the corresponding spectra. 
 
Proposed fragmentation patterns for identification of the phase I metabolites by LC-HR-MS/MS 
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For better description of positions, the basic structure was divided into three sections (Fig. 1), the 
aromatic ring (section 1), the ethyl spacer (section 2), and N,N-diallylamine (section 3). In the 
following, important fragmentation patterns of the mass spectra of DALT, 5-MeO-DALT, and their 
phase I metabolites will be discussed in detail. All masses within this paragraph are the calculated, 
exact masses. 
 
DALT 
The spectrum of the parent compound is given in Fig. S1, no. 1. In addition to the protonated 
molecule with m/z 241.1699 (C16H21N2+), the DALT spectrum showed a characteristic fragment ion 
with m/z 144.0808 (C10H10N+) representing the ethyl indole residue (section 1+2), a fragment ion 
with m/z 117.0701 (C9H9+) representing the indole ring after loss of HCN, and m/z 110.0964 
(C7H12N+) that represented the N,N-diallylmethanimine residue (section 3) following typical 
α-cleavage [14].  
When section 3 in the metabolites was unchanged, fragment ions could be observed with m/z 
110.0964 (nos. 5, 7-13 in Fig. S1) and if N-deallylated (- 40.0313 u) with m/z 70.0651 (2-4 in Fig. 
S1). When sections 1 and 2 were unmodified, fragment ions with m/z 144.0808 (2, 12 in Fig. S1) 
appeared, when mono-hydroxylated (+ 15.9949 u) with m/z 160.0757 (3-5, 7, 8, 11 in Fig. S1), when 
di-hydroxylated (+ 31.9898 u) with m/z 176.0706 (9, 10 in Fig. S1), or when tri-hydroxylated (+ 
47.9847 u) with m/z 192.0655 (13 in Fig. S1). Furthermore, fragment ions with m/z 117.0699 (2-6, 12 
in Fig. S1) were observed in N-deallylated metabolites or in those with an unchanged indole ring. In 
case of ring mono-hydroxylation, ions with m/z 115.0542 (C9H7+) were formed instead (3, 4, 7, 8 in 
Fig. S1), representing the hydroxylated indole ring after loss of HCN and further elimination of 
water. Both fragments were not formed in compounds with multiple hydroxylation sites on the ring 
system or hydroxylations in section 2. Minor fragment ions with m/z 132.0808 (C9H10N+) 
representing methyl indole residues were formed by all compounds with either an un-substituted or 
mono-hydroxylated indole ring (2-5, 7, 8, 11 in Fig. S1).  
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The two hydroxy metabolites (7, 8 in Fig. S1) showed protonated molecule with m/z 
257.1648 (C16H21ON2+) and identical fragments. Besides fragment ion with m/z 160.0757 
(C10H10ON+), no loss of water (- 18.0100 u) could be observed indicating hydroxylation in section 1. 
The spectra of the four di-hydroxy metabolites (9-12 in Fig. S1) showed the protonated molecule with 
m/z 273.1598 (C16H21O2N2+). Three of them (9-11 in Fig. S1) showed a fragment ion with m/z 
231.1128 (C13H15O2N2+) resulting from allyl cleavage (see also fragment ion with m/z 261.1234 in 
spectra nos. 16 and 17 in Fig. S2). Two isomers (9, 10 in Fig. S1) showed an additional fragment ion 
with m/z 148.0393 (C8H6O2N+) indicating that two hydroxylations occurred in section 1. The third 
isomer (11 in Fig. S1) showed a loss of two hydrogens (- 2.0156 u) to give m/z 174.0550 (C10H8O2N+) 
instead of a fragment ion with m/z 176.0706 (C10H10O2N+) representing the same structure with a 
double bond in section 2. A further loss of carbon monoxide (- 27.9950 u) could be observed leading 
to m/z 146.0600 (C9H8ON+). The presence of the fragment ion with m/z 110.0964 (C7H12N+) 
suggested the formation of one aryl hydroxy group in section 1 and one alkyl hydroxy group in 
section 2. The fourth isomeric spectrum (12 in Fig. S1) showed different fragmentation patterns. The 
main fragment ion with m/z 144.0808 (C10H10N+) and m/z 142.0863 (C7H12O2N+) indicated that both 
oxygens were introduced at the N,N-diallylic group in section 3 leaving section 1 and 2 unmodified. 
Instead of a fragment ion with m/z 231.1128 (9-11 in Fig. S1), a shift of one hydrogen (+ 1.0078 u) 
was observed to give a radical cation with m/z 232.1206 (C13H16O2N2+•). Despite the shift, this 
fragment ion allowed for the positions of the hydroxy groups to be established. Either both were 
located at the same allyl group or one hydroxy was located at the nitrogen forming an N-oxide. 
Beyond this, the fragment ion with m/z 100.0757 (C5H10ON+) represented a hydroxylated 
N-allyl-N,N-bis-methyl amine with two possible positions. Either one oxidation led to an N-oxide or 
both hydroxy groups were located at different substituents, although this might be excluded from 
detection of the fragment ion with m/z 232.1206. Thus, the proposed metabolite structure seemed 
more consistent with an N-oxide. In general, N-oxides were eluting later on reversed phase columns 
compared to the parent compounds. A corresponding metabolite representing allylic hydroxylation in 
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section 3 was not detected. As far as the detected hydroxy and di-hydroxy metabolites were 
concerned (7-12 in Fig. S1), the proposed N-oxide had the longest RT (4.5 min) compared to all 
others (RT between 3.4 and 4.3 min), which appear to support this suggestion. Among hydroxy and 
di-hydroxy metabolites, tri-hydroxy metabolite could also be identified (13 in Fig. S1). The mass 
spectrum showed a protonated molecule with m/z 289.1547 (C16H21O3N2+) and a fragment ion with 
m/z 164.0342 (C8H6O3N+) that corresponded to addition of one oxygen (+ 15.9949 u) in contrast to 
the fragment ion with m/z 148.0393 (C8H6O2N+) observed in aryl di-hydroxy metabolites. It 
represented the threefold aryl hydroxylated metabolite.  
Protonated molecules with m/z 255.1492 (C16H19ON2+) revealed two oxo metabolites (5, 6 in 
Fig. S1). The first isomer spectrum (5 in Fig. S1) showed fragment ion analogous to the aryl hydroxy 
metabolites (7, 8 in Fig. S1). However, instead of m/z 115.0542 (C9H7+), a fragment ion with m/z 
117.0699 (C9H9+) was detected that pointed toward an un-substituted indole ring as described above. 
Regarding these fragments, the proposed keto function could only be positioned in section 2. The 
second isomer spectrum (6 in Fig. S1) showed completely different fragmentation patterns compared 
to all other spectra. Both main fragment ion with m/z 214.1101 (C13H14ON2+•) and m/z 173.0709 
(C10H9ON2+) contained the unchanged amine group and calculated chemical formulas could only be 
explained by ring closure with a suggested structure given in spectrum 6 in Fig. S1. The initial step 
may reflect hydroxylation in the amine α-position representing a rather instable hemiaminal. This 
chemical structure could either degrade, oxidized to an amide, or could engage in nucleophilic attack 
of the indole 2-position position. The product after ring closure could explain both main fragment ion 
after loss of the allyl groups (- 41.0391 u), respectively, as well as m/z 146.0600 (C9H8ON+) after 
further loss of hydrocyanic acid (- 27.0109 u). 
A metabolic N-dealkylation step led to a spectrum (2 in Fig. S1) that revealed a protonated 
molecule with m/z 201.1386 (C13H17N2+) and a typical fragment ion with m/z 70.0651 (C4H8N+) 
similar to what was described above. Combinations with mono-hydroxylation led to two isomers (3, 
4 in Fig. S1) with protonated molecule with m/z 217.1335 (C13H17ON2+). Both isomers showed 
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similar fragmentation patterns as aryl hydroxy metabolites (7, 8 in Fig. S1), except for the allyl 
shift and an additional fragment ion with m/z 148.0757 (C9H10ON+), which represented aryl 
hydroxylation in a methylindole species. It should be mentioned that this fragment ion differed from 
fragment ion with m/z 148.0393 (C8H6O2N+) detected in aryl di-hydroxy metabolites (9, 10 in Fig. 
S1). 
 
5-MeO-DALT 
The 5-MeO-DALT spectrum is given in Fig. S2, no. 1. Basic fragmentation patterns were 
analogous to those of DALT. Thus, in addition to the protonated molecule with m/z 271.1805 
(C17H23ON2+), the ethyl indole residue (section 1+2) was represented by fragment ion with m/z 
174.0913 (C11H12ON+), the indole ring after HCN loss by fragment ion with m/z 117.0699 (C9H9+), 
and the iminium ion (section 3) by fragment ion with m/z 110.0964 (C7H12N+). Moreover, an 
additional fragment ion was observed with m/z 159.0679 (C10H9ON+) representing the hydroxy 
ethylindole part following radical loss of a methyl group (see also spectra nos. 3, 18, 21 in Fig. S2). 
When section 3 in the metabolites was unmodified, fragment ions could be observed with m/z 
110.0964 (7-11, 13-17, 19, 20 in Fig. S2) and when N-deallylated (- 40.0313 u), ions with m/z 
70.0651 (2-6 in Fig. S2) were detected. When there was no metabolic change in sections 1 and 2, 
fragment ion with m/z 174.0913 ( 3, 18, 21 in Fig. S2) appeared, when mono-hydroxylated with m/z 
190.0863 (5, 6, 10, 11, 13, 14 in Fig. S2), when di-hydroxylated with m/z 206.0812 (16, 17 in Fig. 
S2), when tri-hydroxylated with m/z 222.0761 (20 in Fig. S2), or when O-demethylated with m/z 
160.0757 (2 in Fig. S2), respectively. O-Demethylation in combination with mono-hydroxylation led 
to fragment ion with m/z 176.0706 (4, 8 in Fig. S2) or, when di-hydroxylation was involved, to a 
fragment ion with m/z 192.0655 (15 in Fig. S2). Again, the fragmented indole ring was represented by 
fragment ion with m/z 117.0699 (2, 3, 10-12 in Fig. S2) or 115.0542 (2, 7 in Fig. S2). Both fragments 
were not formed in compounds with multiple hydroxylations at the ring system, with hydroxylations 
in section 2 (4, 5, 8, 9, 13, 15-21 in Fig. S2), or with aryl-hydroxy-methoxy substituents (6, 14 in Fig. 
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S2). Finally, the methyl indole residues were represented by fragment ion with m/z 132.0808 
(C9H10N+) in all compounds that either displayed an un-substituted or mono-hydroxylated indole ring 
(2, 7 in Fig. S2), except for those hydroxylated in section 2 (9 in Fig. S2). 
The two hydroxy metabolites (13, 14 in Fig. S2) showed a protonated molecule with m/z 
287.1754 (C17H23O2N2+). The first isomer (13 in Fig. S2) showed metabolic hydroxylation in section 
2, identified by a fragment ion with m/z 158.0600 (C10H8ON+) representing the hydroxy ethylene 
indole part after subsequent loss of the O-methyl group and water. For the second isomer (14 in Fig. 
S2), a fragment ion with m/z 162.0550 (C9H8O2N+) represented the di-hydroxy methyl indole part 
after loss of the O-methyl group, which specified the position of hydroxylation in section 1. Three 
di-hydroxy metabolites were detected (16-18 in Fig. S2) with protonated molecules with m/z 
303.1703 (C17H23O3N2+). Two of them (16, 17 in Fig. S2) were consistent with aryl di-hydroxy 
metabolites with fragment ion with m/z 178.0499 (C9H8O3N+: 162.0550 + 15.9949 u) as described 
above. In contrast, the third isomer (18 in Fig. S2) showed a fragment ion with m/z 174.0913 
(C11H12ON+) indicating a loss of both hydroxy groups within section 3. This could be confirmed by 
the detection of ion with m/z 142.0863 (C7H12O2N+: 110.0964 + 31.9899 u). Furthermore, the 
fragment ion with m/z 100.0757 (C5H10ON+) represented hydroxylated N-allyl-N,N-bis-methyl 
amine, as already described for DALT, and again two options could be considered. Either the two 
hydroxy groups were located at different N-allyl positions or one of them was an N-oxide. 
Considering N-oxidation, a comparable fragmentation pattern as for the proposed DALT N-oxide and 
a comparable shift in RT (4.4 min) compared to other metabolites could be observed, again 
suggesting the presence of the N-oxide. Three tri-hydroxy metabolites (19-21 in Fig. S2) were found 
with protonated molecules with m/z 319.1652 (C17H23O4N2+). Isomer one (19 in Fig. S2) showed only 
two fragment ions with m/z 110.0964 (C7H12N+) and 178.0499 (C9H8O3N+). The first fragment ion 
represented a non-hydroxylated section 3, the second fragment ion a tri-hydroxy methylindole after 
loss of the O-methyl group as already described above. Both fragment ions indicated the positions of 
two aryl hydroxy groups presented in section 1 and one in section 2. In isomer two (20 in Fig. S2), all 
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hydroxy groups were positioned in section 1, confirmed by detection of a fragment ion with m/z 
194.0448 (C9H8O4N+) representing threefold hydroxylated methyl indole. Isomer three (21 in Fig. 
S2) exhibited all hydroxy groups on the alkyl side chain in section 3. Confirmation of this assignment 
came from a fragment ion with m/z 174.0913 (C11H12ON+) as described for the spectrum of the parent 
compound and a fragment ion with m/z 158.0812 (C7H12O3N+: 110.0964 + 47.9848 u). Regarding 
fragmentation patterns and RT (4.4 min), the presence of an N-oxide was indicated. 
Three oxo metabolites showed protonated molecules with m/z 285.1598 (C17H21O2N2+) (10-12 
in Fig. S2). According to their common fragmentation patterns, the oxygen positions were consistent 
with section 2 for two of the isomers (10, 11 in Fig. S2) as proven by the presence of fragment ion 
with m/z 110.0964 (C7H12N+) and the loss of carbon monoxide (- 27.9950 u) in fragment ions with 
m/z 190.0863 (C11H12O2N+) to result in formation of m/z 162.0913 (C10H12ON+). It should be 
mentioned that this fragment ion differed from the fragment ion with m/z 162.0550 (C9H8O2N+) 
representing di-hydroxy methylindole regarding loss of the O-methyl group as described above (14, 
16, 17 in Fig. S2). The third isomer (12 in Fig. S2) showed fragmentation patterns similar to those 
described for DALT in spectrum no. 6 in Fig. S1. Fragment ions with m/z 244.1206 (C14H16O2N2+•), 
203.0815 (C11H11O2N2+), and 176.0706 (C10H10O2N+) were considered analogous to fragment ions 
with m/z 214.1101 (C13H14ON2+•), 173.0709 (C10H9ON2+), and 146.0600 (C9H8ON+), respectively. 
N-Dealkylation led to a spectrum (3 in Fig. S2) that showed a protonated molecule with m/z 
231.1492 (C14H19ON2+) and a typical fragment ion with m/z 70.0651 (C4H8N+) as already described 
above. Combinations of N-dealkylation and hydroxylation led to two metabolites with protonated 
molecule with m/z 247.1441 (C14H19O2N2+) (5, 6 in Fig. S2) and a fragment ion with m/z 178.0863 
(C10H12O2N+). This was degraded either to give a fragment ion with m/z 158.0600 (C10H8ON+), 
indicating hydroxylation in section 2, or to a fragment ion with m/z 162.0550 (C9H8O2N+), indicating 
an aryl hydroxylation in section 1. 
O-Demethylation (7 in Fig. S2) led to a protonated molecule with m/z 257.1648 (C16H21ON2+) 
with fragment ions similar to those described for aryl hydroxy DALT (7, 8 in Fig. S1). Two 
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O-demethyl hydroxy metabolites could be postulated (8, 9 in Fig. S2) with protonated molecules 
with m/z 273.1598 (C16H21O2N2+). Fragmentation of the first isomer (8 in Fig. S2) did not differ from 
that obtained from aryl di-hydroxy DALT (9, 10 in Fig. S1) with fragment ions with m/z 162.0550 
(C9H8O2N+) and hydroxylation in section 1. For the second isomer (9 in Fig. S2), a loss of water (- 
18.0100 u) from fragment ion with m/z 176.0706 (C10H10O2N+) to m/z 158.0606 (C10H8ON+) 
indicated hydroxylation in section 2. An O-demethyl di-hydroxy metabolite (15 in Fig. S2) could be 
detected with a protonated molecule with m/z 289.1547 (C16H21O3N2+) and fragment ions similar to 
those identified for aryl tri-hydroxy DALT (13 in Fig. S1). Thus, the two metabolically formed 
hydroxy groups were located in section 1. The spectrum of the O-demethyl N-dealkyl metabolite (2 in 
Fig. S2) showed a protonated molecule with m/z 217.1335 (C13H17ON2+) and fragment ions that did 
not differ from those of N-dealkyl aryl hydroxy DALT (3, 4 in Fig. S1). Further hydroxylation of this 
metabolite (4 in Fig. S2) led to a protonated molecule with m/z 233.1285 (C13H17O2N2+). The position 
of the hydroxy group was thought to be located in section 2 because of the observed fragment ion 
with m/z 148.0757 (C9H10ON+) that excluded the position of the second hydroxy group on the 
methylindole ring. 
 
Proposed fragmentation patterns for identification of the phase II metabolites by LC-HR-MS/MS 
 
In the following, important fragmentation patterns of the mass spectra of DALT, 5-MeO-DALT 
phase II metabolites will be discussed. All masses within the paragraph are the calculated exact 
masses. 
 
DALT 
In general, the conjugates of the aryl mono-hydroxy metabolites showed same fragment ion as the 
underlying phase I metabolites, following conjugate losses of -79.9568 u for sulfates or -176.0321 u 
for glucuronides, with additional fragment ions with m/z 240.0325 (3S, 4S, 7S, 8S in Fig. S3) for 
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sulfates or at 336.1078 (3G, 4G, 7G, 8G in Fig. S3) for glucuronides. These fragment ions 
represented the ethyl indole part (sections 1+2) with + 79.9568 u for sulfates or + 176.0321 u for 
glucuronides. In total, sulfates and glucuronides could be detected for two aryl hydroxy isomers (7S, 
8S, 7G, 8G in Fig. S3) and two N-dealkyl aryl-hydroxy isomers (3S, 4S, 3G, 4G in Fig. S3). 
 
5-MeO-DALT 
Sulfates and glucuronides were found for alkyl hydroxy (13S, 13G in Fig. S4), aryl hydroxy (14S, 
14G in Fig. S4), N-dealkyl alkyl hydroxy (5S, 5G in Fig. S4), N-dealkyl aryl hydroxy (6S, 6G in Fig. 
S4), O-demethyl (7S, 7G in Fig. S4), O-demethyl N-dealkyl (2S, 2G in Fig. S4), and O-demethyl 
N-dealkyl alkyl hydroxy (4S, 4G in Fig. S4) isomers. For O-demethyl alkyl hydroxy (9G in Fig. S4) 
and O-demethyl aryl hydroxy (8G in Fig. S4) metabolites, only glucuronides could be observed. 
Again, in addition to the fragment ions described for phase I metabolites, fragment ions with m/z 
240.0325 (2S, 7S in Fig. S4), 256.0274 (4S in Fig. S4), 270.0431 (5S, 6S, 13S, 14S in Fig. S4), 
336.1078 (2G, 7G in Fig. S4), 352.1027 (4G, 8G, 9G in Fig. S4), or 366.1183 (5G, 6G, 13G, 14G in 
Fig. S4) were detected for sulfates or glucuronides of metabolites with hydroxy groups on the 
ethylindole moiety (sections 1+2). 
 
Proposed metabolic pathways  
 
According to the identified metabolites, metabolic pathways could be proposed as depicted in Fig. 2 
for DALT and in Fig. 3 for 5-MeO-DALT.  
 
DALT 
Three hydroxylations were expected on the indole ring although only two of them could be detected 
(7, 8 in Fig. 2), most probably due to insufficient separation or low abundance of the third isomer. 
These mono-hydroxy metabolites were further hydroxylated to two isomeric di-hydroxy metabolites 
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(9, 10) and these finally to a tri-hydroxy metabolite (13). Aliphatic hydroxylation in section 2 
formed a precursor for the corresponding oxo metabolite (5) and the ring-rearranged metabolite (6). 
N-dealkylation (2) and N-oxidation could also be observed. The following combinations could be 
proposed from these observations: aromatic and aliphatic hydroxylation in section 2 (11), 
N-oxidation with aliphatic hydroxylation in section 3 (12), and N-dealkylation with aromatic 
hydroxylation (3, 4). Glucuronidation and sulfation could be observed for both isomers of the aryl 
hydroxylated metabolites with (3, 4) and without (7, 8) N-dealkylation.  
 
5-MeO-DALT 
The metabolic pathways were similar to those observed for DALT including aromatic and aliphatic 
hydroxylation at various sites. Again, the indole ring was expected to bear three different 
hydroxylation sites but although only one of them could be detected (14 in Fig. 3), presumable due to 
similar reasons mentioned above. These mono-hydroxy metabolites were further hydroxylated to two 
isomeric di-hydroxy metabolites (16, 17) and finally to a tri-hydroxy metabolite (20). Aliphatic 
hydroxylation in section 2 (13) formed a precursor for the corresponding two oxo metabolites (10, 
11) and the ring-rearranged metabolite (12). N-Dealkylation (3), N-oxidation, or O-demethylation (7) 
could also be observed. The following combinations could be proposed: aromatic and aliphatic 
hydroxylation in section 2 (19), N-oxidation with aliphatic mono- or di-hydroxylation in section 3 
(18, 21), N-dealkylation with aliphatic (5) or aromatic (6) hydroxylation, O-demethylation with 
aliphatic (9) or aromatic mono- (8) or di-hydroxylation (15), with N-dealkylation (2), or 
N-dealkylation with aliphatic hydroxylation (4). Glucuronidation and sulfation could be observed for 
alkyl (13) or aryl hydroxy metabolites (14), for O-demethyl (7) or N-dealkyl metabolites (3), and 
O-demethyl hydroxy metabolites (2, 4-6). For O-demethyl alkyl (9) or aryl hydroxy metabolites (8), 
only glucuronides were detected. 
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Comparing the pathways of both drugs, it is obvious that one of the di-hydroxy metabolites of 
DALT (9 in Fig. 2) should be identical to the O-demethyl hydroxy metabolite of 5-MeO-DALT (8 in 
Fig. 3). Similarly, the tri-hydroxy metabolite of DALT (13 in Fig. 2) would be identical to the 
O-demethyl di-hydroxy metabolite of 5-MeO-DALT (15 in Fig. 3), thus, accounting for identical 
spectra and retention times. The O-demethyl metabolite of 5-MeO-DALT (7 in Fig. 3) could be 
identical either to the hydroxy metabolite 7 (Fig. 2) of DALT with slightly different spectra and 
retention times or to the undetected hydroxy metabolite.  
 
Microsomal incubations of DALT and 5-MeO-DALT 
 
Unfortunately, no human urine samples were available to confirm that the metabolites in rat urine 
would also be found in human urine. According to many former studies [16, 20, 27-34], combination 
of rat urine studies with incubations of new drugs with pHLM provides a tool for good predictions of 
phase I metabolites for detection in human urine. Katagi et al. discussed the transferability for other 
N,N-di-alkyl tryptamines [16]. After pHLM incubation, all phase I metabolites could be detected for 
DALT and metabolites 3, 5-7, 10-14, 16-18, and 21 (Fig. 3) for 5-MeO-DALT. Therefore, it seems 
reasonable to assume that at least some of these metabolites might also be found in human urine. 
For the initial CYP activity screening, the metabolites were detected after incubation with 
individual CYPs. The relative involvement of the single CYPs in metabolic pathways of DALT are 
given in Table 1 and those of 5-MeO-DALT in Table 2. The relative involvement of individual CYPs 
was defined in relation to the highest peak abundances during precursor ion monitoring of the formed 
metabolites. A CYP was defined as mainly involved if the corresponding relative peak abundance 
values were above 50 %. According to these findings, the following isoenzymes were mainly 
involved in given metabolic steps: for DALT, CYP3A4 in all types of hydroxylations, CYP2D6 in 
oxidation to the oxo metabolite, CYP2C19 and CYP3A4 in N-dealkylations; for 5-MeO-DALT, 
CYP3A4 in all type of hydroxylations, CYP1A2 and CYP2D6 in oxidation to the oxo metabolites, 
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CYP2C19 and CYP3A4 in N-dealkylations, and CYP2D6 in O-demethylations. Given that several 
CYP enzymes were involved in the metabolism of both drugs, one might expect that CYP enzyme 
polymorphisms might be of minor toxicological relevance. 
 
Toxicological detection of DALT and 5-MeO-DALT by GC-MS, LC-MSn, and LC-HR-MS/MS 
 
The doses of 1 mg/kg BM administered to rats corresponded to low human single doses of about 10 
mg scaled by dose-by-factor approach according to Sharma et al. [35]. As described above, these 
doses corresponded to the suggested dose for 5-MeO-DALT [9-11]. The corresponding urine 
samples were used for the detectability studies. As already discussed, no human urine samples were 
available and thus, the main target for human urinalysis could not be elucidated. However, the 
SUSAs cover all metabolites detected in rat urine including those identified in pHLM with their 
conjugates. From the experience gained in the last years, the possibility that consumption of these 
drugs and identification of their metabolites could be overlooked seems rather low. 
Using GC-MS, only DALT could be screened for via the metabolites given in Table 3 with the 
corresponding fragment ions, their relative abundances, and their retention indices. 5-MeO-DALT 
and its metabolites could be monitored only in rat urine after high dose administration and might 
therefore be detectable only in overdose cases. The corresponding GC-MS data are published 
elsewhere [23].  
Using LC-MSn, both drugs could be screened for via the metabolites given in Table 4 using the 
protonated precursor ions, characteristic MS2 and MS3 fragment ions, and retention times. The 
LC-HR-MS/MS SUSA allowed for monitoring an intake of both drugs by detecting the following 
metabolites with the given HR-MS/MS spectra: for DALT, spectra nos. 1, 4, 7, 10, 13 in Fig. S1 and 
3S, 4S, 8S, 3G, 4G, 7G, 8G in Fig. S3; for 5-MeO-DALT, spectra nos. 2 in Fig. S2 and 7S, 13S, 5G, 
6G, 7G, 9G, 13G, 14G in Fig. S4. Reconstructed LC-HR-MS/MS ion chromatograms with the given 
m/z of the most abundant metabolites following work-up of a rat urine sample (low dose) are depicted 
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in Fig. 4. The metabolites of DALT (part A) with the most abundant peak areas were 
aryl-hydroxy-glucuronide isomer 1 (7G in Fig. S3), its isomer 2 (8G in Fig. S3), aryl-hydroxy isomer 
1 (7 in Fig. S1), and aryl-tri-hydroxy metabolite (13 in Fig. S1). The metabolites of 5-MeO-DALT 
(part B) with the most abundant peak areas were O-demethyl-glucuronide (7G in Fig. S4), 
alkyl-hydroxy-glucuronide (13G in Fig. S4), N-dealkyl-aryl-hydroxy-glucuronide (6G in Fig. S4), 
aryl-hydroxy-glucuronide (14G in Fig. S4), and N-dealkyl-alkyl-hydroxy-glucuronide metabolite 
(5G in Fig. S4), respectively. Fortunately, because various targets could be detected, the risk of false 
negative results caused by ion suppression of a particular target was limited.  
To assess the general performance of the SUSAs, the limits of detection (LOD) for the parent 
compounds were determined in the particular approaches although they were not the main targets 
chosen for urinalysis. Urine samples spiked with the corresponding drugs in decreasing 
concentrations were analyzed with all SUSAs and the signal-to-noise ratio of 3 was defined as LOD. 
For GC-MS, LC-MSn, and LC-HR-MS/MS SUSA, the LODs for DALT in urine were 10, 10, and 1 
ng/mL and for 5-MeO-DALT 50, 10, and 1 ng/mL, respectively. Considering the fact, that for 
GC-MS, 5 mL and for both LC-MS approaches only 0.1 mL of urine was processed for work-up, the 
LODs for DALT were comparable for GC-MS and LC-MSn, but as expected much lower for 
LC-HR-MS/MS. The rather high LOD for 5-MeO-DALT in GC-MS might be caused by reduced 
ionization, as the peak area of the reference standards also differed in the same range.  
 
 
Conclusions 
 
The two new psychoactive substances DALT and 5-MeO-DALT were extensively metabolized in 
rats. It could be assumed that those metabolites should also be found in human urine considering the 
results obtained from pHLM incubations. CYP2C19, CYP2D6, and CYP3A4 were mainly involved 
in DALT and 5-MeO-DALT metabolism. The LC-MSn and LC-HR-MS/MS SUSAs should be 
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suitable for reliably monitoring an intake of both drugs. The GC-MS SUSA should be able to 
monitor DALT intake, but 5-MeO-DALT only in overdose cases.  
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Table 1 Relative involvement of human CYP isoenzymes in metabolic pathways of DALT  
CYP isoenzymes Hydroxylations,  
all types (%) 
Oxidations to oxo 
metabolites (%) 
N-dealkylations (%) 
CYP1A2 11 35 46 
CYP2A6 1 0 1 
CYP2B6 12 4 5 
CYP2C8 3 0 5 
CYP2C9 3 2 20 
CYP2C19 4 13 69 
CYP2D6 25 100 25 
CYP2E1 3 0 5 
CYP3A4 100 5 100 
CYP3A5 0 0 0 
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Table 2 Relative involvement of human CYP isoenzymes in metabolic pathways of 5-MeO-DALT  
CYP isoenzymes Hydroxylations,  
all types (%) 
Oxidations to oxo 
metabolites (%) 
N-dealkylations (%) O-Demethylations 
(%) 
CYP1A2 1 100 23 0 
CYP2A6 0 0 1 0 
CYP2B6 0 3 3 0 
CYP2C8 0 0 5 0 
CYP2C9 1 0 39 3 
CYP2C19 0 20 100 21 
CYP2D6 0 92 29 100 
CYP2E1 0 0 1 0 
CYP3A4 100 17 88 15 
CYP3A5 0 0 5 0 
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Table 3 Targets for GC-MS SUSA monitoring DALT with molecular masses, five most abundant 
fragment ions, their relative abundances, and retention indices according to Kovats [36]  
Compound Molecular  mass (u) 
GC-MS fragment ions (m/z) and 
their relative abundance (%) 
Retention 
index 
DALT-M (HO-) AC 298 110 (100), 146 (9), 160 (3), 257 (1), 298 (1) 2310 
DALT-M (N-dealkyl-HO-) 
2AC 300 
159 (100), 70 (59), 146 (56), 201 (53), 
300 (10) 2690 
DALT-M (tri-HO-) 3AC 414 110 (100), 373 (15), 146 (10), 160 (3), 414 (1) 2400 
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Table 4 Targets for LC-MSn SUSA monitoring DALT or 5-MeO-DALT with protonated 
precursor ions, characteristic MS2 and MS3 fragment ions, and retention time (RT) 
Targets for SUSA Precursor 
ions (m/z) 
MS2 fragment ions (m/z), 
and relative intensity (%) 
MS3 fragment ions (m/z) 
on the ion given in bold 
and relative intensity 
(%)  
RT 
(min) 
DALT-M  
(N-dealkyl-HO-aryl-glucuronide) 
393 160 (100), 217 (87), 148 
(47), 336 (38), 324 (21) 
160: 132 (100), 160 (79), 
116 (64) 
1.5 
DALT-M  
(tri-HO-aryl-) 
289 110 (100), 247 (7), 192 (5), 
176 (4), 229 (3) 
110: 81 (100), 69 (12), 79 
(11), 68 (10), 69 (10) 
2.3 
DALT-M  
(HO-aryl-glucuronide) isomer 1 
433 257 (100), 336 (39), 160 
(33), 215 (1), 376 (1) 
257: 110 (100), 160 (62), 
111 (7), 98 (3), 77 (2) 
2.9 
DALT-M  
(HO-aryl-glucuronide) isomer 2 
433 336 (100), 160 (36), 257 
(20), 318 (2), 405 (1) 
336: 160 (100), 132 (2), 
115 (1) 
4.7 
DALT-M  
(di-HO-aryl-) 
273 176 (100), 231 (91), 232 
(68), 148 (21), 174 (8) 
176: 148 (100), 130 (3), 
82 (1) 
5.2 
DALT-M  
(HO-aryl-) 
257 110 (100), 160 (6), 215 (3), 
79 (1), 82 (1) 
110: 81 (100), 68 (29), 80 
(19), 70 (11), 55 (9) 
5.3 
     
5-MeO-DALT-M  
(N-dealkyl-HO-alkyl-glucuronide) 
423 178 (100), 366 (65), 354 
(38), 190 (29), 247 (29) 
178: 146 (100), 118 (9), 
122 (3) 
1.6 
5-MeO-DALT-M  
(O-demethyl-glucuronide) 
433 257 (100), 160 (33), 336 
(23) 
257: 110 (100), 160 (76), 
98 (2), 81 (1), 80 (1) 
3.0 
5-MeO-DALT-M  
(HO-aryl-glucuronide) 
273 366 (100), 287 (74), 190 
(41), 164 (3), 348 (3) 
366: 190 (100), 158 (2), 
175 (2) 
5.0 
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Legends to Figures 
 
Fig. 1 Structure of DALT (A) and 5-MeO-DALT (B) with corresponding division into sections to aid 
the identification procedure of metabolites 
 
Fig. 2 Proposed metabolic pathways for DALT (numbering according to Fig. S1) 
 
Fig. 3 Proposed metabolic pathways for 5-MeO-DALT (numbering according to Fig. S2) 
 
Fig. 4 Reconstructed LC-HR-MS ion chromatograms with the corresponding protonated molecular 
exact masses (+/- 5 ppm) indicating the given DALT metabolites (part A) and 5-MeO-DALT 
metabolites (part B) in rat urine samples after low dose administration 
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Fig. 1 Structure of DALT (A) and 5-MeO-DALT (B) with corresponding division into sections to aid the 
identification procedure of metabolites  
80x92mm (300 x 300 DPI)  
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Fig. 3 Proposed metabolic pathways for 5-MeO-DALT (numbering according to Fig. S2)  
217x159mm (300 x 300 DPI)  
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Fig. 3 Proposed metabolic pathways for 5-MeO-DALT (numbering according to Fig. S2)  
217x159mm (300 x 300 DPI)  
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Fig. 4 Reconstructed LC-HR-MS ion chromatograms with the corresponding protonated molecular exact 
masses (+/- 5 ppm) indicating the given DALT metabolites (part A) and 5-MeO-DALT metabolites (part B) in 
rat urine samples after low dose administration  
125x79mm (300 x 300 DPI)  
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values, proposed chemical structures, accurate masses, calculated elemental formulas, and mass error values in 
parts per million (ppm) rounded to two decimals 
 
  
Page 39 of 50 Analytical & Bioanalytical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Page 40 of 50Analytical & Bioanalytical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Page 41 of 50 Analytical & Bioanalytical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Page 42 of 50Analytical & Bioanalytical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Page 43 of 50 Analytical & Bioanalytical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Fig. S2 LC-HR-MS/MS spectra of 5-MeO-DALT and its phase I metabolites arranged according to their 
precursor values, proposed chemical structures, accurate masses, calculated elemental formulas, and mass error 
values in parts per million (ppm) rounded to two decimals 
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Fig. S3 LC-HR-MS/MS spectra of DALT phase II metabolites arranged according to their precursor values, 
proposed chemical structures, accurate masses, calculated elemental formulas, and mass error values in parts 
per million (ppm) rounded to two decimals 
 
  
Page 46 of 50Analytical & Bioanalytical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Page 47 of 50 Analytical & Bioanalytical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Page 48 of 50Analytical & Bioanalytical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Page 49 of 50 Analytical & Bioanalytical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Fig. S4 LC-HR-MS/MS spectra of 5-MeO-DALT phase II metabolites arranged according to their precursor 
values, proposed chemical structures, accurate masses, calculated elemental formulas, and mass error values in 
parts per million (ppm) rounded to two decimals 
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